Allergy Therapeutics (AGY)
AGY Share PerformanceMore
|52 week high||39.50 10/10/17|
|52 week low||24.00 18/04/18|
|52 week change||-2.25 (-8.26%)|
|4 week volume||1,372,336 30/03/18|
Latest News« previous» nextMore
16/03/2018 - 16:38 RNS
RNS Number: 0414I Allergy Therapeutics PLC 16 March 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Grant of Awards under Long Term Incentive Plan Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company's Long Term Incentive Plan ("LTI...
16/03/2018 - 13:53 RNS
RNS Number: 0170I Allergy Therapeutics PLC 16 March 2018 16 March 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director/PDMR Shareholding Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that, on 15 March 2018, Tunde Otulana, Non-Executive Dir...
07/03/2018 - 15:25 StockMarketWire
Allergy Therapeutics posted a moderately lower first-half loss after a rise in revenue was offset by higher expenses. Pre-tax...
07/03/2018 - 10:30 RNS
RNS Number: 8865G Allergy Therapeutics PLC 07 March 2018 Hardman Research: Clinical development towards submission Clinical development towards submission: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share d...
07/03/2018 - 08:00 RNS
RNS Number: 9016G Allergy Therapeutics PLC 07 March 2018 Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a meeting and call for analysts to provide an update on the Group, followed by a Q&A session, at 0930 GMT today. Dial-in details are: +44 (0) 1452 580733. Conference ID: 2485568. Allergy Therapeutics plc ("Allergy Th...
28/02/2018 - 08:00 RNS
RNS Number: 1512G Allergy Therapeutics PLC 28 February 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics prepares for manufacturing and clinical development of Polyvac Peanut allergy product - Specialist CMO AGC Biologics engaged - 28 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialt...
Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in London
15/02/2018 - 10:24 StockMarketWire
If you are looking for some investment ideas for your ISA, then come along the Shares and AJ Bell Investor Evening in Lo...
12/02/2018 - 09:38 StockMarketWire
Allergy Therapeutics plc announced Monday that recruitment has been completed in its grass allergy Phase II study with r...
|Dividend yield||0 %|
Latest discussion posts More
“AGY needs to see more directors like Otulana backing this company by buying shares in the company on the open market. This purchase shows that this particular board member ...”▼
“Slides from the Investor Evening - 7 March: http://s1.moneyam.com/pdfs/20180307-investor-evening/nick-wykeman-allergy-therapeutics.pdf”▼
“Morning. Short TV interview with Manuel Llobert (CEO) and Nick Wykeman (CFO) following this morning's ...”▼
Codes & Symbols
|Symbols||AGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY|